SELLAS Releases Annual Letter to Shareholders
April 28 2020 - 8:30AM
SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the
“Company”), a late-stage clinical biopharmaceutical company focused
on the development of novel cancer immunotherapies for a broad
range of cancer indications, today announced that it has released
its annual letter to shareholders.
In the shareholder letter Angelos Stergiou, MD,
ScD h.c., SELLAS’ President & Chief Executive Officer,
addresses the Company's product development, anticipated clinical
milestones, and operational plans for 2020. Excerpted here are two
key passages: “As I write this letter, we are in unprecedented
times and all of us at SELLAS wish you and your families to remain
safe and healthy. Although we are now all living through this
COVID-19 pandemic, I hope to convey a theme of growth and
transformation at SELLAS as we are further advancing our clinical
programs and remain diligent in our business development and
licensing efforts. We greatly appreciate your dedication and
support of our company over the years and we are confident that
2020 will demonstrate that your loyalty was well-placed.”
“SELLAS remains clear in its mission and vision
to develop and deliver complex and innovative treatments for
patients battling cancer. Against the backdrop of the current
pandemic, we are doing our best to manage those elements of our
business that we believe we can control – progressing our assets,
generating clinical and immunobiological data, executing on
clinical development and progressing with business development
opportunities. As of this writing, the three ongoing clinical
trials for our lead clinical candidate, galinpepimut-S (GPS), have
not been materially impacted. And our business development efforts
seeking a licensee for our Phase 3 ready nelipepimut-S (NPS) are
also continuing. As such, we plan to continue to report data from
our programs as it becomes available throughout the remainder of
2020 and into 2021.”
To view the full letter, please go to www.sellaslifesciences.com
or click on the following link:
http://www.sellaslifesciences.com/Shareholder-Letter
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical
biopharmaceutical company focused on the development of novel
cancer immunotherapeutics for a broad range of cancer indications.
SELLAS’ lead product candidate, GPS, is licensed from Memorial
Sloan Kettering Cancer Center and targets the WT1 protein, which is
present in an array of tumor types. GPS has potential as a
monotherapy or in combination to address a broad spectrum of
hematologic malignancies and solid tumor indications. SELLAS’
second product candidate, NPS, is a HER2-directed cancer
immunotherapy with potential for the treatment of patients with
early stage breast cancer with low to intermediate HER2 expression,
otherwise known as HER2 1+ or 2+, which includes triple negative
breast cancer patients, following standard of care. For more
information on SELLAS, please
visit www.sellaslifesciences.com.
Forward-Looking Statements
This press release contains forward-looking
statements. All statements other than statements of historical
facts are “forward-looking statements,” including those relating to
future events. In some cases, forward-looking statements can be
identified by terminology such as “plan,” “expect,” “anticipate,”
“may,” “might,” “will,” “should,” “project,” “believe,” “estimate,”
“predict,” “potential,” “intend,” or “continue” and other words or
terms of similar meaning. These statements include, without
limitation, statements related to the Company’s plans for clinical
development of for GPS, including the timing of clinical results,
and the potential for GPS as a drug development candidate, and its
business development efforts for NPS. These forward-looking
statements are based on current plans, objectives, estimates,
expectations and intentions, and inherently involve significant
risks and uncertainties. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks and
uncertainties associated with the COVID-19 pandemic and its impact
on the Company’s clinical plans and business strategy,
immune-oncology product development and clinical success thereof,
the uncertainty of regulatory approval, and other risks and
uncertainties affecting SELLAS and its development programs as set
forth under the caption “Risk Factors” in SELLAS’ Annual Report on
Form 10-K filed on March 13, 2020 and in its other SEC filings.
Other risks and uncertainties of which SELLAS is not currently
aware may also affect SELLAS’ forward-looking statements and may
cause actual results and the timing of events to differ materially
from those anticipated. The forward-looking statements herein are
made only as of the date hereof. SELLAS undertakes no obligation to
update or supplement any forward-looking statements to reflect
actual results, new information, future events, changes in its
expectations or other circumstances that exist after the date as of
which the forward-looking statements were made.
Investor Contacts Adam Holdsworth PCG Advisory
646-862-4607 adamh@pcgadvisory.com
Investor Relations SELLAS Life Sciences Group, Inc. 917-438-4353
info@sellaslife.com
Source: SELLAS Life Sciences Group
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Aug 2024 to Sep 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Sep 2023 to Sep 2024